Ken Griffin Mannkind Corp Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$4.05 - $5.43 $163,620 - $219,372	40,400 Added 19.5%	247,600 $1.29 Million
Q1 2024 May 15, 2024	BUY	$3.25 - $5.27 $97,825 - $158,627	30,100 Added 17.0%	207,200 $938,000
Q4 2023 Feb 14, 2024	BUY	$3.34 - $4.29 $339,010 - $435,435	101,500 Added 134.26%	177,100 $644,000
Q3 2023 Nov 14, 2023	BUY	$3.91 - $5.45 $30,107 - $41,965	7,700 Added 11.34%	75,600 $312,000
Q2 2023 Aug 14, 2023	BUY	$3.72 - $4.79 $4,092 - $5,269	1,100 Added 1.65%	67,900 $276,000
Q1 2023 May 15, 2023	SELL	$3.95 - $5.63 $396,185 - $564,689	-100,300 Reduced 60.02%	66,800 $273,000
Q4 2022 Feb 14, 2023	SELL	$3.02 - $5.37 $126,236 - $224,466	-41,800 Reduced 20.01%	167,100 $880,000
Q3 2022 Nov 14, 2022	SELL	$2.99 - $4.35 $813,878 - $1.18 Million	-272,200 Reduced 56.58%	208,900 $646,000

219

133M

1.43M

851K

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.7B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.